Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Last updated: May 7, 2025
Sponsor: Masonic Cancer Center, University of Minnesota
Overall Status: Completed

Phase

N/A

Condition

Anemia

Aplastic Anemia

Telomere Related Diseases

Treatment

Cyclophosphamide

Anti-thymocyte globulin

Alemtuzumab

Clinical Study ID

NCT02162420
2013OC127
MT2013-34C
  • Ages < 70
  • All Genders

Study Summary

Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 0 - 70 years

  • Acceptable hematopoeitic stem cell donor

  • Dyskeratosis Congenita (DC) with evidence of BM failure defined as:

  • requirement for red blood cell and/or platelet transfusions or

  • requirement for G-CSF or GM-CSF or erythropoietin or

  • refractory cytopenias having one of the following three

  • platelets <50,000/uL or transfusion dependent

  • absolute neutrophil count <500/uL without hematopoietic growth factorsupport

  • hemoglobin <9g/uL or transfusion dependent

  • Diagnosis of DC with a triad of mucocutaneous features:

  • oral leukoplakia

  • nail dystrophy

  • abnormal reticular skin hyperpigmentation, or

  • Diagnosis of DC with one of the following:

  • short telomeres (under a research study)

  • mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1)

  • mutation in shelterin complex (TINF2)

  • mutation in telomere-capping complex (CTC1)

  • Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:

  • Refractory cytopenia defined by bone marrow cellularity <50% (with < 30%residual hematopoietic cells)

  • Diagnosis of SAA with refractory cytopenias having one of the following three:

  • platelets <20,000/uL or transfusion dependent

  • absolute neutrophil count <500/uL without hematopoietic growth factor support

  • absolute reticulocyte count <20,000/uL

  • Severe Aplastic Anemia (SAA) requiring a 2nd transplant

  • Graft failure as defined by blood/marrow chimerism of < 5%

  • Early myelodysplastic features

  • With or without clonal cytogenetic abnormalities

  • Adequate organ function defined as:

  • cardiac: left ventricular ejection fraction ≥ 35% with no evidence ofdecompensated heart failure

  • pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement

  • renal: Glomerular filtration rate (GFR) ≥30% predicted

  • Voluntary written consent

Exclusion

Exclusion Criteria:

  • Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis onbiopsy

  • Pregnant or lactating

  • Uncontrolled infection

  • Prior radiation therapy (applies to SAA patients only)

  • Diagnosis of Fanconi anemia based on DEB

  • Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with >30% blasts

Study Design

Total Participants: 61
Treatment Group(s): 6
Primary Treatment: Cyclophosphamide
Phase:
Study Start date:
January 10, 2015
Estimated Completion Date:
March 11, 2025

Connect with a study center

  • University of Minnesota Medical Center, Fairview

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.